Trimeprazine
ADVERTISEMENT
- Molecular formula
- C18H22N2S
- CAS Number
- 84-96-8
- IUPAC Name
- trimethyl-(1-methyl-2-phenothiazin-10-yl-ethyl)ammonium
- Molecular Weight
- 372.54g/mol
- Melting Point
- (Celsius)
- Boiling Point
- (Celsius)
- Density
- 1.2020g/cm3
- Synonyms
- Thiazinamium
Identification
Interesting facts
Interesting Facts about Trimethyl-(1-methyl-2-phenothiazin-10-yl-ethyl)ammonium
Trimethyl-(1-methyl-2-phenothiazin-10-yl-ethyl)ammonium is a fascinating compound with unique properties and applications. Here are some intriguing aspects of this compound:
- Diverse Applications: This compound is significant in the field of pharmaceuticals, particularly in the development of psychoactive medications. Compounds similar to this one have been studied for their effects on neurotransmitter systems in the brain.
- Phenothiazine Derivative: Its structure includes a phenothiazine moiety, a component found in various antipsychotic and antihistaminic drugs. The phenothiazine nucleus is known for its ability to interact with dopamine receptors.
- Charge Properties: The trimethylammonium group renders this compound a quaternary ammonium salt, imparting unique solubility and reactivity characteristics. The positive charge can enhance the interaction with biological targets, making it a candidate for drug development.
- Synthetic Relevance: The synthesis of this compound can involve various methods, including multistep reactions that can lead to modifications in its therapeutic actions. This aspect is crucial for chemists looking to optimize drug efficacy.
- Research Potential: Ongoing studies explore the potential of trimethyl-(1-methyl-2-phenothiazin-10-yl-ethyl)ammonium in the domain of neuropharmacology. Researchers are investigating the compound's mechanisms, side effects, and overall therapeutic window.
In summary, trimethyl-(1-methyl-2-phenothiazin-10-yl-ethyl)ammonium is more than just a chemical entity; it represents a cornerstone in the ongoing pursuit of understanding complex biological systems and advancing medication development.